Modules 1-4 & Independent Reading Post-Test and Evaluation

Participant demographics:

Question Title

* 1. Full Name:

Question Title

* 2. Please indicate credentials

Question Title

* 3. License number (Florida providers will be reported to CE Broker)

Question Title

* 4. Please provide email address for CME certificate delivery. 

Question Title

* 5. How many credit(s) are you claiming:

DEA MATE Curriculum Part 1 Post-test (a passing score of 90% is required).

Question Title

* 6. Addictive disease is low dopamine in which of the following:

Question Title

* 7. Which of the following signs provide a signal to practitioners to screen for alcohol use disorder or substance use disorder?

Question Title

* 8. Medically managed intensive inpatient treatment (i.e. hospital admission) is Level III of the ASAM Criteria Levels of Treatment for Addictive Disease.

Question Title

* 9. Addictive disease is influenced by stress, environmental cues, and exposure to substances.

Question Title

* 10. CFR 42, Part 2-Confidentiality of Substance Use Disorder Patient Records safeguards patients diagnosed with substance use disorder at a higher level than HIPAA.

Question Title

* 11. Buprenorphine maintenance includes which of the following:

Question Title

* 12. Dr. Dole and Dr. Nyswander started treating patients under Heroin addiction with Methadone in 1964, which started a new era of treating opioid addiction.

Question Title

* 13. Naltrexone blocks the effects of opioids and the euphoric effect of alcohol use.

Question Title

* 14. Successful treatment for moderate to severe addictive disease includes which of the following?

Question Title

* 15. Practitioners need to ensure a patient with opioid use disorder is in adequate withdrawal (COWS>12; Fentanyl may be higher) before Buprenorphine induction.

T